Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

An FGFR4 Germline Variant Activates STAT3 Signaling

DOI: 10.1158/2159-8290.CD-RW2015-241 Published February 2016
  • Article
  • Info & Metrics
Loading
  • Major finding: An FGFR4 substitution promotes STAT3 signaling by revealing a membrane-proximal STAT3 binding site.

  • Mechanism: Variant rs351885-G/A results in a substitution that alters the FGFR4 transmembrane segment.

  • Impact: STAT3 inhibitors may be effective in patients with cancer who have the germline rs351885-A SNP.

The rs351885-G/A single-nucleotide polymorphism (SNP) results in an amino-acid substitution (p.Gly388Arg) in the transmembrane domain of FGFR4. The Arg388 allele occurs in about 50% of patients with cancer and is associated with a poor prognosis. However, the mechanism by which it promotes tumorigenesis is unknown. To investigate the role of the FGFR4 p.Gly388Arg variant, Ulaganathan and colleagues generated a knock-in mouse with the mouse homolog of the p.Gly388Arg allele (p.Gly385Arg). These mice had no obvious phenotypic defects, but cultured mouse embryonic fibroblasts (MEF) had an increased proliferation rate. Bioinformatics analyses of the FGFR transmembrane domain identified a STAT3 YXXQ binding motif in close proximity to the amino acid substitution, partially overlapping with the transmembrane region. The glycine to arginine substitution exposed this STAT3 binding site, positioning it proximal to the membrane, and resulted in increased STAT3 activity in both mouse and human cells expressing the Arg388 variant. Knock-in MEFs homozygous for the p.Gly385Arg allele exhibited a higher dependency on STAT3 for survival, suggesting addiction to enhanced STAT3 signaling. STAT3 was activated by an FGFR4 Arg388 variant lacking the tyrosine kinase domain, and targeting of STAT3 to the inner plasma membrane was sufficient to increase its activation. Mutations in FGFR4 that moved the STAT3 binding site away from the plasma membrane reduced STAT3 phosphorylation and cell proliferation, suggesting that proximity of the STAT3 binding site to the plasma membrane is essential for its phosphorylation and activity. Consistent with these findings, in mouse models of breast and lung cancer harboring the FGFR4 variant, the Arg385 allele was associated with enhanced STAT3 activity and proliferation. Taken together, these findings demonstrate that the rs351885-G/A SNP results in an FGFR4 p.Gly388Arg substitution that exposes a membrane-proximal STAT3 binding site, thereby promoting STAT3 activation. This result suggests that STAT3 inhibitors may have potential in treating patients with cancer who have the rs351885-G/A SNP.

Ulaganathan VK, Sperl B, Rapp UR, Ullrich A. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site. Nature 2015 Dec 16 [Epub ahead of print].

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (2)
February 2016
Volume 6, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
An FGFR4 Germline Variant Activates STAT3 Signaling
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
An FGFR4 Germline Variant Activates STAT3 Signaling
Cancer Discov February 1 2016 (6) (2) OF8; DOI: 10.1158/2159-8290.CD-RW2015-241

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
An FGFR4 Germline Variant Activates STAT3 Signaling
Cancer Discov February 1 2016 (6) (2) OF8; DOI: 10.1158/2159-8290.CD-RW2015-241
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Signaling

  • The STRIPAK Complex Regulates the Hippo Kinase Cascade
  • Peritumoral YAP and TAZ Expression Suppresses Tumor Growth in Mice
  • RAF Binding Preferences Dictate RAS-Mediated Tumorigenesis
Show more Signaling
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement